In the phase III PIONEER clinical trial program, oral semaglutide was shown to reduce glycated hemoglobin and body weight compared with placebo and active comparators in patients with T2D, with no new safety signals reported
Sci Transl Med (2017) 9(420):eaal3765
Pu Z, Yang Y, Qin S, Li X, Cui C, Chen W
Replacing fluid or blood loss due to wounds is an especially essential benefit of IV therapy for traumatic brain injury patients, who may have an imbalance of fluids or electrolytes and considerable blood loss
This is where commercialisation strategy becomes decisive
The Broader GI Side-Effect Picture Sulfur burps are one piece of a larger gastrointestinal adjustment that most GLP-1 patients experience